Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 2009
Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014)
O Matzinger, F Roelofsen, L Mineur, et al.
The British Journal of Surgery
|
February 28, 2021
Sphincter-saving surgery after neoadjuvant therapy for ultra-low rectal cancer where abdominoperineal resection was indicated: 10-year results of the GRECCAR 1 trial
P Rouanet, M Rivoire, S Gourgou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2022
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)
D Basile, C Broudin, J F Emile, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
February 15, 2011
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial]
M Barhoumi, F Mornex, F Bonnetain, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 31, 2009
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
M Ychou, J-L Raoul, J-Y Douillard, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Continuum of care and survival in patients with metastatic colorectal cancer: results of the real-world prospective, longitudinal cohort PROMETCO study
M Koopman, R Garcia-Carbonero, C Pinto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2020
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study
F Pagès, T André, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 12, 2024
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
D Baron, T Pace Loscos, R Schiappa, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
October 13, 2018
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial
Y Touchefeu, R Guimbaud, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 13, 2020
Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929
F Pagès, T André, J Taieb, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 2009
Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014)
O Matzinger, F Roelofsen, L Mineur, et al.
The British Journal of Surgery
|
February 28, 2021
Sphincter-saving surgery after neoadjuvant therapy for ultra-low rectal cancer where abdominoperineal resection was indicated: 10-year results of the GRECCAR 1 trial
P Rouanet, M Rivoire, S Gourgou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2022
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)
D Basile, C Broudin, J F Emile, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
February 15, 2011
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial]
M Barhoumi, F Mornex, F Bonnetain, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 31, 2009
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
M Ychou, J-L Raoul, J-Y Douillard, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Continuum of care and survival in patients with metastatic colorectal cancer: results of the real-world prospective, longitudinal cohort PROMETCO study
M Koopman, R Garcia-Carbonero, C Pinto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2020
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study
F Pagès, T André, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 12, 2024
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
D Baron, T Pace Loscos, R Schiappa, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
October 13, 2018
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial
Y Touchefeu, R Guimbaud, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 13, 2020
Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929
F Pagès, T André, J Taieb, et al.
Page
of 4